cMYC abnormal activation and KRAS mutation play a critical role in MM pathogenesis.31–33 We observed that PM demonstrated approximately a 4-fold superior antiproliferation activity compared to panobinostat on c-MYC/KRAS12V transformed BaF3 cells (Supplementary Fig. 1b). Here, KRAS is linked to Miyoshi myopathy.